← Leaderboards
Feng Lin
Child Health And Human Development
$12,867,349
Attributed
$16,233,454
Total exposure
15
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,233,454 · 15
By mechanism
R01$13,067,125 · 8
R61$1,127,000 · 1
R21$1,017,841 · 3
R41$658,068 · 2
K01$363,420 · 1
Top collaborators
- K. P. Connie Tam8 shared
- James E Dennis4 shared
- Thomas Alan Hamilton2 shared
- Lina Lu2 shared
Others in their field
Top investigators on “Knockout Mice”
- Kc Kent Lloyd · University Of California At Davis$88,263,392
- Alan F Horwitz · University Of Virginia Charlottesville$34,297,512
- C Ronald Kahn · Joslin Diabetes Center$34,076,871
- Stephen A Murray · University Of Pittsburgh At Pittsburgh$32,860,542
- Gary K Owens · University Of Virginia$26,781,146
- Arthur L. Beaudet · Baylor College Of Medicine$25,180,624
Research focus
Knockout MiceT-LymphocyteMediatingIn VitroIn VivoNovel TherapeuticsProteinsCellsTargeted TreatmentReagentRecombinantsBaseKnock-OutComplementComplement ActivationCell SurfaceProductionPathway InteractionsCd6 AntigenSignal TransductionFuturePathogenesisTissuesT Cell Response
Grant awards (47)
Development of a first-in-class complement inhibitor for treating complement-mediated hematologic diseases$563,500
R61 · FY2025 · HL · contact PI
Role of CDCP1 in the pathogenesis of autoimmune uveitis$504,011
R01 · FY2025 · EY · contact PI
Development of a first-in-class complement inhibitor for treating complement-mediated hematologic diseases$563,500
R61 · FY2024 · HL · contact PI
Role of CDCP1 in the pathogenesis of autoimmune uveitis$504,011
R01 · FY2024 · EY · contact PI
New mechanisms by which complementýregulates the pathogenesis of experimental autoimmune uveitis$402,500
R01 · FY2024 · EY · contact PI
A novel regulator of Pseudomonas aeruginosa keratitis$565,590
R01 · FY2023 · EY · contact PI
Role of CDCP1 in the pathogenesis of autoimmune uveitis$504,011
R01 · FY2023 · EY · contact PI
New mechanisms by which complementýregulates the pathogenesis of experimental autoimmune uveitis$402,500
R01 · FY2023 · EY · contact PI
A novel regulator of Pseudomonas aeruginosa keratitis$548,620
R01 · FY2022 · EY · contact PI
Development of a novel antibody-drug conjugate for treating T-cell lymphoma.$402,680
R41 · FY2022 · CA · contact PI
New mechanisms by which complementýregulates the pathogenesis of experimental autoimmune uveitis$390,425
R01 · FY2022 · EY · contact PI
A novel regulator of corneal wound healing and Pseudomonas aeruginosa keratitis$390,425
R01 · FY2022 · EY · contact PI
A novel regulator of Pseudomonas aeruginosa keratitis$548,622
R01 · FY2021 · EY · contact PI
New mechanisms by which complementýregulates the pathogenesis of experimental autoimmune uveitis$402,500
R01 · FY2021 · EY · contact PI
A novel regulator of corneal wound healing and Pseudomonas aeruginosa keratitis$390,425
R01 · FY2021 · EY · contact PI
Role of CD6 in the pathogenesis of autoimmune uveitis$384,362
R01 · FY2021 · EY · contact PI
Development of a new drug for treating autoimmune uveitis$255,388
R41 · FY2021 · EY · contact PI
A novel regulator of Pseudomonas aeruginosa keratitis$565,004
R01 · FY2020 · EY · contact PI
A novel regulator of corneal wound healing and Pseudomonas aeruginosa keratitis$401,875
R01 · FY2020 · EY · contact PI
Role of CD6 in the pathogenesis of autoimmune uveitis$396,250
R01 · FY2020 · EY · contact PI
A NOVEL REGULATOR OF CORNEAL WOUND HEALING$400,000
R01 · FY2019 · EY · contact PI
Role of CD6 in the pathogenesis of autoimmune uveitis$396,250
R01 · FY2019 · EY · contact PI
Development of new models of AMD$348,448
R21 · FY2019 · EY · contact PI
Role of CD6 in the pathogenesis of autoimmune uveitis$396,250
R01 · FY2018 · EY · contact PI
Local inhibition of complement to improve MSC-based therapy for diabetes$356,625
R01 · FY2018 · DK · contact PI
Role of CD6 in the pathogenesis of autoimmune uveitis$396,250
R01 · FY2017 · EY · contact PI
Local inhibition of complement to improve MSC-based therapy for diabetes$356,625
R01 · FY2017 · DK · contact PI
Local inhibition of complement to improve MSC-based therapy for diabetes$356,625
R01 · FY2016 · DK · contact PI
Complement and Osteoporosis$378,438
R01 · FY2015 · AR · contact PI
Local inhibition of complement to improve MSC-based therapy for diabetes$356,625
R01 · FY2015 · DK · contact PI
Complement and Osteoporosis$370,423
R01 · FY2014 · AR · contact PI
Validation of CD6 as a New Target for Treating Multiple Sclerosis$196,143
R21 · FY2014 · NS · contact PI
Complement and Osteoporosis$358,601
R01 · FY2013 · AR · contact PI
Validation of CD6 as a New Target for Treating Multiple Sclerosis$237,750
R21 · FY2013 · NS · contact PI
Complement and Osteoporosis$387,688
R01 · FY2012 · AR · contact PI
Role of SUSD4 in Retinal Development and Function$235,500
R21 · FY2010 · EY · contact PI
Synergy between T cells and Complement in EAE$49,866
R01 · FY2010 · NS · contact PI
Synergy between T cells and Complement in EAE$237,137
R01 · FY2009 · NS · contact PI
Synergy between T cells and Complement in EAE$237,137
R01 · FY2008 · NS · contact PI
Synergy between T cells and Complement in EAE$237,137
R01 · FY2007 · NS · contact PI
Synergy between T cells and Complement in EAE$244,220
R01 · FY2006 · NS · contact PI
Synergy between T cells and Complement in EAE$250,097
R01 · FY2005 · NS
Cytokines and Complement in Nephritis and Colitis$127,930
K01 · FY2005 · DK
Cytokines and Complement in Nephritis and Colitis$128,250
K01 · FY2004 · DK
Cytokines and Complement in Nephritis and Colitis$107,240
K01 · FY2003 · DK
Determination Of Protective Levels Of Maternal Antibody$0
Z01 · FY2001 · HD
Determination of Protective Levels of Maternal Antibody to Group B Streptococcus$0
Z01 · FY2000 · HD